Ken Griffin Fulcrum Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2025 May 15, 2025	BUY	$2.88 - $5.08 $5,760 - $10,160	2,000 Added 16.95%	13,800 $39,000
Q4 2024 Feb 14, 2025	SELL	$2.97 - $4.84 $565,488 - $921,536	-190,400 Reduced 94.16%	11,800 $55,000
Q3 2024 Nov 14, 2024	BUY	$3.18 - $9.74 $563,178 - $1.72 Million	177,100 Added 705.58%	202,200 $721,000
Q2 2024 Aug 14, 2024	BUY	$5.98 - $9.31 $128,570 - $200,165	21,500 Added 597.22%	25,100 $155,000
Q1 2024 May 15, 2024	SELL	$6.7 - $12.0 $27,470 - $49,200	-4,100 Reduced 53.25%	3,600 $33,000
Q4 2023 Feb 14, 2024	SELL	$3.18 - $6.86 $24,804 - $53,508	-7,800 Reduced 50.32%	7,700 $51,000
Q3 2023 Nov 14, 2023	BUY	$3.25 - $6.08 $3,900 - $7,296	1,200 Added 8.39%	15,500 $68,000
Q2 2023 Aug 14, 2023	SELL	$2.26 - $3.8 $35,030 - $58,900	-15,500 Reduced 52.01%	14,300 $47,000
Q1 2023 May 15, 2023	BUY	$2.83 - $13.99 $19,244 - $95,132	6,800 Added 29.57%	29,800 $84,000
Q4 2022 Feb 14, 2023	BUY	$5.01 - $8.35 $27,555 - $45,925	5,500 Added 31.43%	23,000 $167,000
Q3 2022 Nov 14, 2022	SELL	$4.92 - $9.1 $37,884 - $70,070	-7,700 Reduced 30.56%	17,500 $142,000

128

55.6M

869K

93.3K

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $340M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.